Search Results
Apr 30, 2026, 08:51 ET U.S. Prescription Drug Spending Poised to Cross $1 Trillion
Clinics saw the fastest growth at 19%, driven by specialty and injectable drugs, particularly cancer biologics and newly available treatments for rare diseases like amyotrophic lateral sclerosis (ALS) and amyloidosis that had few or no options until recently.Hospitals saw 9.6% growth, driven
More news about: ASHP (American Society of Health-System Pharmacists)
Apr 30, 2026, 08:32 ET OneUnited Bank Introduces "Who's Your Ma Honey? Show" to Transform Undeserved Shame Into Empowerment
celebrated for purpose-driven campaigns and multicultural brand strategy. A unique and respected voice in marketing and entrepreneurship, McDowell brings a rare combination of creative insight and empathy to the show.More information about the "Who's Your Ma Honey? Show visit
More news about: OneUnited Bank
Apr 30, 2026, 08:30 ET Icons in Ink Debuts in Cleveland as a Landmark Exhibition of Comic Art and History
The exhibition brings together an extraordinary array of rare and vintage comic books, original artwork, and archival materials drawn from private collections and major publishers - many of which are being presented
More news about: Maltz Museum
Apr 30, 2026, 08:27 ET SmartAC Expands AI Leadership with Senior Engineering Team Led by CTO Matt Robillard
customers.Under Robillard's leadership, SmartAC is building an engineering organization designed for long-term data advantage. The team brings rare experience operating at the intersection of real-time data ingestion, physics-informed modeling, and machine learning at scale—capabilities critical
More news about: SmartAC
Apr 30, 2026, 08:00 ET Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio
demonstrates strong patient uptake and rapid access timelines – – Advancing differentiated mitochondrial-targeted pipeline across rare and age-related indications – NEEDHAM, Mass., April 30, 2026 /PRNewswire/
More news about: Stealth BioTherapeutics Inc.
Apr 30, 2026, 07:47 ET NAMSA and Lexitas Announce Strategic Partnership to Deliver End-to-End Ophthalmic Medical Device Development
designDeep therapeutic-area coverage across anterior and posterior segment ophthalmic indications, including cell and gene therapy, rare disease and advanced modalitiesGlobal reach across the U.S., Europe, and Asia-PacificA single, accountable team under a
More news about: NAMSA
Apr 30, 2026, 07:33 ET Caveman to Casanova launches nationally: a first-of-its-kind relationship app built by therapists, designed for men, and built for couples ready to actually reconnect
Board. Named EY Entrepreneur of the Year (2024), Inc. Female Founders 100 (2022), and Stevie Awards Woman of the Year in Franchising (2022), Erin brings rare dual fluency in clinical practice and high-growth entrepreneurship to every Pash Company venture. The portfolio includes Caveman to Casanova, Pot Mamas,
More news about: Pash Co.
Apr 30, 2026, 07:00 ET Keenova Therapeutics to Report First Quarter 2026 Financial Results on May 12, 2026
KeenovaKeenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty
More news about: Keenova Therapeutics
Apr 30, 2026, 07:00 ET ClerkMinutes Launching National Meeting Minutes Day, Marking the Largest Single-Day AI Deployment in Local Government
America. "Most companies focus on large cities and overlook smaller communities. What Dustin and the HeyGov team have done with ClerkMinutes is rare. They've built a product that directly addresses a real need for Clerks, and the level of adoption they're seeing speaks for itself.""I chose
More news about: HeyGov/ClerkMinutes
Apr 30, 2026, 06:00 ET The Cigna Group Reports Strong First Quarter 2026 Results, Raises 2026 Outlook
formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person
More news about: The Cigna Group
Apr 30, 2026, 05:56 ET No Traffic Lights, Just Paradise: Why NYT Named Camiguin a 'Must-Visit' in 2026
imagination of travelers seeking serenity, adventure, and authentic local experiences. Praised for its "zero traffic lights" charm, the island promises a rare combination of unspoiled natural beauty and easy accessibility.
More news about: Department of Tourism Philippines
Apr 30, 2026, 05:00 ET VISTAJET UNVEILS SUMMER PRIVATE WORLD COLLECTION 2026: IMMERSIVE JOURNEYS AT THE EDGE OF THE EXTRAORDINARY
before landing beside a glacier for a guided trek across ancient ice. The journey continues by kayak through a maze of floating icebergs, offering a rare, intimate perspective of this pristine environment — before returning via a scenic rail transfer. Designed for families with children aged eight and
More news about: VistaJet
Apr 30, 2026, 04:11 ET DREAME AURORA Debuts in Silicon Valley, Introducing a New Vision for Human-Centric Intelligent Devices
capabilities through its modular design architecture. The AURORA LUX crafts heirloom-grade luxury tech pieces through exquisite artisanal craftsmanship and rare, premium materials. The flagship product integrates technology and aesthetics, offering a balanced, unified experience that stands as the benchmark for
More news about: DREAME AURORA
Apr 30, 2026, 03:00 ET 3 Rare Earth Metals Keeping Pentagon Planners Up At Night
Chinese-origin rare earth materials cannot be used in American defense systems. Every major defense contractor — Lockheed, RTX, Northrop Grumman — must have a domestic, China-free rare earth alloy supply chain by that date. That supply chain barely exists.China didn't just dominate the rare earth alloy
More news about: OilPrice.com
Apr 30, 2026, 02:31 ET Dreame Unveils Next-Generation Personal Care Lineup at DREAME NEXT 2026, Backed by 1,230% North American Growth
accredited by Intercoiffure Mondial (ICD), the global association representing the world's top hairdressers — a level of professional endorsement that is rare for a consumer electronics brand. At the event, Dreame Personal Care also joined forces with ICD to stage the Dreame Hair Show, an immersive runway
More news about: Dreame Technology
Apr 29, 2026, 17:57 ET PACSUN HOSTS CO-CREATED LOCKER ROOM EVENT WITH THE LOS ANGELES RAMS
streetwear, and activewear, Pacsun partners with the best brands at the intersection of fashion, music, art, and sport to offer curated collections, rare and exclusive products, and creative collaborations on every level to inspire the next generation. Founded in 1980 in Newport, CA, Pacsun is now co-created
More news about: Pacsun
Apr 29, 2026, 17:15 ET Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
once-weekly1Novo Nordisk continues to build on its leadership in hemophilia research to help address unmet needs for people living with this rare and potentially life-threatening conditionPLAINSBORO, N.J. and BAGSVÆRD, Denmark, April
More news about: Novo Nordisk
Apr 29, 2026, 17:07 ET Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
once-weekly1Novo Nordisk continues to build on its leadership in hemophilia research to help address unmet needs for people living with this rare and potentially life-threatening conditionPLAINSBORO, N.J. and BAGSVÆRD, Denmark, April
More news about: Novo Nordisk
Apr 29, 2026, 16:05 ET Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential
More news about: Viking Therapeutics, Inc.
Apr 29, 2026, 15:06 ET Amy Watts Joins Greenfield Savings Bank's Wealth Management Team
futures."Steve Hamlin, Senior Vice President and Senior Trust Officer at GSB, expressed enthusiasm about Watts joining the team. "Amy brings a rare combination of technical expertise, empathy, and a genuine commitment to helping people. Her relationship-driven approach aligns perfectly with our
More news about: Greenfield Savings Bank
Apr 29, 2026, 13:41 ET Norgine anuncia la autorización de comercialización de la Comisión Europea para XOLREMDI® (mavorixafor)
Treatment. Disponible en: https://rarediseases.org/rare-diseases/whim-syndrome/. Consultado en abril de 20263. Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor,
More news about: Norgine B.V.
Apr 29, 2026, 12:41 ET Global Hydrocephalus Market is projected to reach USD 10.17 Billion by 2030
patients, and increasing the size of the treatable patient population. Shunt complications such as infection, malfunctioning devices, over-drainage and in rare cases irreversible brain injury or meningitis are hurdles impacting the marketplace; these factors continue to limit wider adoption and the push for
More news about: Allied Market Research
Apr 29, 2026, 11:49 ET Phagenesis nomme Stephen Oesterle, MD, au conseil d'administration
croissance et de la création de valeur", a déclaré Oern Stuge, MD, MBA, président du conseil d'administration de Phagenesis. "Il apporte une combinaison rare de connaissances cliniques, de perspectives stratégiques et d'expérience dans la mise au point de technologies qui définissent des catégories. Son arrivée
More news about: Phagenesis
Apr 29, 2026, 10:14 ET Sagicor Life Insurance Company Appoints Eric Sandberg as President
driving our next phase of growth," said Andre Mousseau, President and Chief Executive Officer, Sagicor Financial Company Ltd.Mr. Sandberg brings a rare combination of leadership experience across risk, actuarial, pricing, asset-liability management (ALM), and finance, along with annuities expertise,
More news about: Sagicor Life Insurance Company
Apr 29, 2026, 10:12 ET Norgine gibt die Marktzulassung der Europäischen Kommission für XOLREMDI® (Mavorixafor) bekannt, die erste zugelassene Behandlung für Patienten mit WHIM-Syndrom in der Europäischen Union
Behandlung. Erhältlich bei: https://rarediseases.org/rare-diseases/whim-syndrome/. Zugriff im April 20263. Badolato R, Alsina L, Azar A, et al. Eine randomisierte Phase-3-Studie mit Mavorixafor,
More news about: Norgine B.V.